"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
Potassium Acetate Injection,USP must be diluted before use.
To avoid potassium intoxication, infuse potassium containing solutions slowly. Potassium replacement therapy should be monitored whenever possible by continuous or serial electrocardiography (ECG). Serum potassium levels are not necessarily dependable indicators of tissue potassium levels.
In patients with diminished renal function, administration of solutions containing potassium ions may result in potassium retention.
Solutions containing acetate ion should be used with great care in patients with metabolic or respiratory alkalosis.Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency.
This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature,and they require large amounts of calcium and phosphate solutions which contain aluminum.Research indicates that patients with impaired kidney function,including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 µg per kg per day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration of TPN products and of the lock-flush solutions used in their administration.
Do not administer unless solution is clear and seal is intact.Discard unused portion.
Potassium replacement therapy should be guided primarily by ECG monitoring and secondarily by the serum potassium level.
High plasma concentrations of potassium may cause death by cardiac depression, arrhythmias or arrest.
Use with caution in the presence of cardiac disease, particularly in digitalized patients or in the presence of renal disease.
Solutions containing acetate ion should be used with caution as excess administration may result in metabolic alkalosis.
Animal reproduction studies have not been conducted with potassium acetate.It is also not known whether potassium acetate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium acetate should be given to a pregnant woman only if clearly needed.
Last reviewed on RxList: 11/10/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Potassium Acetate Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.